The following is a summary of “Chronic graft-versus-host disease myelitis successfully treated with rituximab,” published in ...

rituximab might also inhibit T-cell activation. A synergistic effect has been noted in vitro following administration of corticosteroids to B-cell lines, with accentuation of B-cell cytotoxicity ...

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated ...

Patients were randomised to receive Calquence with chemotherapy bendamustine and Biogen and Genentech’s Rituxan (rituximab) or placebo plus ... "AstraZeneca secures first BTK approval in first-line ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

An additional rituximab dose in patients with pemphigus and at least one predictor of relapse may reduce the relapse rate, according to the results of a multicenter French study.

Moreover, the cells demonstrated improved growth and, compared to similarly treated controls, produced significantly higher yields of protein-based drugs such as Herceptin and Rituximab ...

Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL, making it the first and only BTK inhibitor ...

On average, patients had already received four lines of therapy ... CAR-T cell therapy who then received CAR-NK cell therapy plus rituximab, 45% responded with 30% achieving complete remission.

Depleting B cells with targeted antibodies such as rituximab (anti-CD20 mAb ... it the world’s first anti-PD-1 mAb for the first-line treatment of SCLC. What’s more, Henlius has conducted ...